PDCD1 and neoplasm: Tumor mutational burden (TMB), defined as the number of somatic nonsynonymous mutations per mega-base in tumor cells, correlates with favorable outcomes with anti-PD-1 treatment among various types of tumors, such as melanoma and NSCLC [92].